H
eart failure (HF) is the leading cause of death worldwide: the current 5-year mortality after diagnosis of HF is 50%, and the 1-year mortality for those with end-stage disease is 50%. 1, 2 In the United States alone, ≈5.7 million people suffer from HF at a cost of $37.2 billion. 2 The progression of HF stems, in part, from the development of cardiac fibrosis. 3 Fibrosis is a form of scarring that increases the rigidity of muscular tissue, decreases cardiac contractility, and can lead to lethal arrhythmias. Cardiac fibrosis arises from the aberrant, persistent stimulation of fibroblasts in a pathological attempt to repair tissue that is damaged during maladaptive remodeling. [4] [5] [6] [7] Although current therapeutic strategies for patients in HF are primarily aimed at stimulating contractility and reducing vasoconstriction, without a complimentary approach to block or reverse the development of fibrosis, treatment options often represent a bridge to cardiac transplantation.
ACE (angiotensin-converting enzyme) inhibitors (including enalapril) are the current standard of care for HF, demonstrating a consistent reduction in risk of death. 8, 9 ARBs (angiotensin-receptor blockers) are used when the patient cannot tolerate ACE inhibitors, although the effect on clinical end points has been less consistent. 10, 11 Development of a combination therapy that increases the efficacy of ARBs would expand clinical options in the case that ACE inhibitors are contraindicated. To this end, the inhibition of vasoactive peptides has been of interest. Neprilysin is an endopeptidase that degrades various vasoactive peptides, including ANF (atrial natriuretic peptide) and BNP (brain natriuretic peptide). Thus, neprilysin inhibition in concert with an ARB reduces hypertension-ultimately limiting maladaptive cardiac remodeling. A first-inclass combination drug consisting of an ARB (valsartan [VAL] ) and the neprilysin inhibitor LBQ657 (sacubitril [SAC] ) was recently shown to be well tolerated, reducing blood pressure without significant angioedema in human studies. 12 Importantly, a double-blind randomized trial PARADIGM-HF [Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure] comparing enalapril to the Novartis compound LCZ696 (or SAC/VAL) was conducted in HF patients with reduced ejection fraction, showing that LCZ696 was superior to enalapril in reducing risks of death and hospitalization. 13 Although LCZ696 certainly has vasodilatory effects, it is possible that there are direct and indirect effects of this combination therapy on the development of fibrosis. Ang II (angiotensin II) signaling leads to the development of fibrosis indirectly via blood pressure modulation and directly via fibroblast activation.
14 Indeed, the ARB losartan causes regression of cardiac fibrosis and improved diastolic function independent of reduced blood pressure. 15, 16 Another study has also established a potentially direct antifibrotic role for BNP in the remodeling ventricle; BNP null mice displayed a significant increase in focal fibrotic lesions within the ventricle in a mouse model of pressure overload. 17 Evaluation of the effect of SAC/VAL in a rat model of myocardial infarction demonstrated reduced perivascular fibrosis and improved cardiac function. 18 This study confirmed that VAL inhibited fibrosis in vitro; however, the direct effect of SAC/VAL on cardiac fibroblast (CF) was not studied in this context.
CFs express all 3 natriuretic peptide receptors (Npr1/ NPRA, Npr2/NPRB, and Npr3/NPRC), and as such are expected to respond functionally to elevations in ANF by elevating cGMP levels. 19 Of these receptors, NPRA binds both ANF and BNP and is the receptor most closely associated with canonical natriuretic peptide signaling via cGMP and PKG. NPRA, as well as its congeners, undergoes ligand-mediated internalization and sequestration via clathrin-mediated pathways. 20 There is complicated cross-talk between ANF, TGF (transforming growth factor)-β1, Ang II, and cGMP that regulates NPRA expression both at the gene and protein level, as well as its guanylate cyclase activity, and these mechanisms
WHAT IS NEW?
• 
WHAT ARE THE CLINICAL IMPLICATIONS?
• The clinical efficacy of LCZ696 in heart failure patients with reduced ejection fraction cannot be fully explained by the reduction in systemic blood pressure by the combination of angiotensin receptor blockade and increased atrial natriuretic peptide levels.
• Our study suggest that the clinical efficacy of LCZ696 may partially stem from the direct amelioration of cardiac fibroblast activation and the development of fibrosis by blocking pathological suppression of PKG signaling.
• Our results suggest that LCZ696 may prove useful in ameliorating cardiac fibrosis and diastolic dysfunction in heart failure patients with preserved ejection fraction.
are not fully understood in the context of disease. [21] [22] [23] [24] [25] [26] It is conceivable, therefore, that SAC/VAL might exert protective effects via this ANF-NPRA-PKG signaling axis. We conducted a preclinical trial to evaluate the role of SAC/VAL in the direct inhibition of cardiac fibrosis. We found that SAC/VAL was more effective than the molar equivalent dose of VAL at reducing cardiac hypertrophy, diastolic dysfunction, and cardiac fibrosis in a mouse model of pressure overload-induced HF. We found that SAC/VAL decreased the total number of fibroblasts present in the heart and altered their genetic program in a manner consistent with a more quiescent, less activated phenotype. In vitro studies revealed that although VAL acts primarily against TGF-β1/Ang II-induced CF proliferation, addition of sacubitrilat (the active metabolite of the neprilysin inhibitor in SAC/VAL) inhibited activation and myofibroblast transition. The antifibrotic effect of SAC/VAL is at least partially because of the inhibition of Rho signaling via stabilization of ANF-induced PKG signaling. Taken together, the results of this study shed light on potential mechanisms of SAC/VAL efficacy in HF with reduced ejection fraction via acting on CF.
METHODS
The authors declare that all supporting data are available within the article and in the Data Supplement.
Animal Husbandry and Transverse Aortic Constriction Surgery
All animal studies were approved by the University of Rochester Medical Center Animal Care and Use Committee. C57Bl6/J males (Jackson Laboratories, Bar Harbor, ME) were purchased at 8 weeks of age and raised to 12 weeks of age in the vivarium facility with ad libitum access to standard chow and water. Mice were anesthetized with 2.0% isoflurane, placed on a heated surgical board, and given subcutaneous 2.5 mg/kg flunixin (Banamine). After hair removal, a midline cervical incision was made to expose the trachea. A 22-gauge (PE 90) plastic intubation catheter was noninvasively inserted through the mouth and advanced into the trachea; proper placement was viewed through the cervical incision. The catheter was connected to a volume-cycled ventilator supplying supplemental oxygen with a tidal volume of 225 to 250 μl and a ventilation rate of 120 to 130 strokes/minute. Surgical-plane anesthesia was subsequently maintained with 1% to 1.5% isoflurane. The cervical incision was closed with Vicryl 6-0 suture. A left thoracotomy was performed as follows: Skin was incised and chest cavity opened at the level of the second intercostal space. A transverse section of the aorta (between the innominate and left carotid arteries) was isolated. Transverse aortic constriction (TAC) was created by placing a 6.0 silk ligature securely around the transverse aorta and a 27-gauge needle, causing complete occlusion of the aorta. The needle was then removed, restoring a lumen with severe stenosis. Lungs were reinflated, and the chest was closed with Vicryl 6-0 suture. Muscle and skin were sutured with Vicryl 6-0 suture in a running subcuticular pattern. After returning to independent breathing, the mouse was removed from the ventilator and allowed to recover in a clean cage on a heated pad. Buprenorphine was provided every 12 hours for 72 hours postsurgery in accordance with the University Committee on Animal Research guidelines.
Drug Administration
Human patients receive a target dose of 97/103 mg (SAC/VAL) twice daily when prescribed LCZ696 (≈5 mg/kg per day for 80 kg patient). VAL and SAC dissociate in aqueous medium, and sacubtril is metabolized in vivo to the neprilysin inhibitor LBQ657. The SAC/VAL used in our animal studies was obtained from Novartis (Basel, Switzerland) and is the identical formulation of LCZ696. However, the selection of appropriate dosing of LCZ696 in nonhuman species introduces several challenges due to factors such as differential intrinsic potencies of VAL and LBQ657 for the human versus the animal target receptor AT1 (angiotensin II type-1) and neprilysin, differential pharmacokinetics, and differential interspecies rates/levels of hydrolysis of SAC prodrug to the active LBQ657. Dosing was based on pharmacokinetics and pharmacodynamics studies demonstrating optimal dosages required to increase atrial natriuretic peptide immunoreactivity in plasma (readout of neprilysin inhibition) and renin concentration (AT1 receptor inhibition). 27 Published doses of VAL in mice are typically in the range of 10 to 50 mg/kg per day, which inhibit AT1 and neprilysin. Two studies have been published to date with oral gavage dosing of LCZ696 (6 and 60 mg/kg per day, respectively) in mice. 28, 29 However, it is not clear whether the impact on AT1 receptor activity and neprilysin inhibition is equivalent to that observed in humans with currently available data. For animal experiments, we initially used 114 mg/kg per day LCZ696 (consisting of 52 mg/kg per day of VAL and 62 mg/kg per day of SAC). Following experimental evidence regarding toxicity (likely gastritis) at 114 mg/kg per day LCZ696, and further consultation with Novartis, we reduced dosing to 57 mg/kg per day LCZ696. The comparable equimolar dose of VAL (26 mg/ kg per day, also called 1× or low dose) used for the remainder of the experiments matches the plasma exposure of VAL achieved by administering 57 mg/kg per day LCZ696. Fiftytwo milligram per kilogram per day VAL used as comparator in initial studies did not lead to toxicity and was retained as a 2× molar equivalent comparator (also called high dose), reflecting twice the plasma exposure of VAL achieved with 57 mg/kg per day LCZ696. Drugs and saline controls were administered by twice daily oral gavage at 2 mL/kg per dose. Solutions were sterile filtered before gavage. Gavage was performed as normal the day before TAC surgery, skipped on the day of the surgery to allow the animals recovery time. Twice-daily gavage resumed on day 1 postoperation and was continued throughout the remainder of the 28-day period.
Echocardiography and Blood Pressure Analysis
Echocardiographic analysis was performed using a Vevo2100 echocardiography machine (VisualSonics, Toronto, Canada) and a linear-array 40 MHz transducer (MS-550D). Left ventricular (LV) systolic and diastolic measurements were captured in M-mode from the parasternal short axis. Tissue Doppler was used to measure diastolic dysfunction in a subset of mice on day 28. All echocardiography was performed in a blinded fashion. Systolic/diastolic blood pressure and resting heart rate were evaluated by a noninvasive tail-cuff plethysmograph, on which mice were trained before measurements (Visitech Systems, Apex, NC).
RNA Isolation From Whole Hearts
Mouse ventricular fibroblasts were isolated by Langendorff perfusion. Briefly, the heart was removed from the animal and the aorta cannulated and secured on a blunted 21G needle and the heart digested with 1 mg/mL collagenase II (305 U/μg, Worthington Biochemicals, Lakewood, NJ) as described previously. 30 The ventricular tissue was then removed from the cannula, shredded using forceps, and passed through a 100 μm filter to obtain a single cell suspension. The cardiomyocytes were separated by gravity sedimentation for 12 minutes at 37°C, and then the remaining supernatant was centrifuged at 1000 rpm for 5 minutes at 4°C to pellet the nonmyocyte population. CFs were isolated by plating the resuspended pellet for 2 hours at 37°C and washing the attached cells (fibroblasts) 3 times with PBS before RNA isolation. RNA isolation was performed on cardiomyocyte and CF fractions using trizol/chloroform extraction as previously described.
30,31

Quantitative Polymerase Chain Reaction and Analysis
Genomic DNA was removed by treating isolated RNA samples with Turbo DNAse (Ambion/Thermo Fisher, Waltham, MA). cDNA was generated using 500 to 1000 ng RNA for all subsequent experiments using iScript Reverse Transcriptase kit (Bio-Rad, Hercules, CA) per manufacturer's instructions. Gene expression was examined by quantitative polymerase chain reaction using iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) and the CFX Connect Real-Time PCR Detection System (Bio-Rad). Relative mRNA levels were normalized to ribosomal 18s and calculated using the 2 −(∆∆Ct) method.
Histology and Analysis
When fully unconscious, the mouse chest cavity was opened, and the heart tissue was perfused with calcium-and magnesium-free PBS, followed by fixation with 10% neutral buffered formalin solution overnight and subsequent histological processing, paraffin embedding, and sectioning.
Fibrosis
Five-micrometer sections were generated at 10 equally spaced levels from each heart, mounted on slides, and stained with PicroSirius Red according to manufacturer's instructions (Abcam, Cambridge, MA). Images were captured at 10× on a BX51 epifluorescence microscope (Olympus, Shinjuku, Japan) using circularly polarized light to generate a birefringent (red/thick and green/thin) signal from collagen fibers.
To evaluate fibrosis, areas of interest (epicardial, perivascular, and interstitial) were defined in ImageJ (National Institutes of Health). The extent of epicardial fibrosis was determined by the number of positive pixels in the green and red channels in an area defined by a freehand line along the epicardium extended in 100 pixels from the epicardial surface, divided by the arc length of the epicardial freehand line. The extent of perivascular fibrosis was determined by calculating the ratio of the area of the positive pixels surrounding the vessel to the total vessel area. The extent of interstitial fibrosis was determined by calculating the number of positive pixels in the nonepicardial, nonperisvascular area of the section, and dividing by the total nonepicardial, nonperivascular area.
Cardiomyocyte Hypertrophy
To evaluate the extent of cardiomyocyte hypertrophy, sections were stained with 4',6-diamidino-2-phenylindole (DAPI) (to visualize nuclei, 350/50ex-460/50em) and wheat germ agglutinin (to visualize cell borders, 620/60ex-700/75em) scanned at 20× on a BX70 confocal microscope (Olympus, Shinjuku, Japan). No less than 250 transverse myocytes per animal were evaluated for cross-sectional area.
Assessment of Nonmyocyte Population
Sections were stained with DAPI (to visualize nuclei), Alexa 488-conjugated isolectin-B4 (Sigma-Aldrich, St. Louis, MO), and rabbit-anti-vimentin (Abcam, Cambridge, MA) followed by a donkey-anti-rabbit secondary antibody conjugated to Alexa 594 (Invitrogen, Carlsbad, CA Dilutions data are given in Table I in the Data Supplement.
Primary Cell Isolation-Mouse
Neonatal mouse CFs were isolated as previously described. 30 Briefly, Primary CFs were isolated from neonatal mouse hearts by differential plating. Hearts were removed from neonatal mice on the day of birth. Ventricles were isolated and transferred to a solution of 0.8 mg/mL collagenase type II (Worthington Labs) and finely minced. Hearts were then agitated in 10 mL of collagenase solution in 4 cycles of 10 minutes each, collecting cells at each step by centrifugation. Cells were strained through a 70 μm filter and plated on a 10 cm dish for 1 hour to enrich adherent cells (nonmyocyte fraction).
Primary Cell Isolation-Human HF
CF was isolated from patient-derived tissue as previously published, 30 following written informed consent under the auspices of an approved University of Rochester IRB protocol (No. 52958). Briefly, left ventricle tissue that would normally be discarded during ventricular assist device (VAD) implantation was freshly obtained and dissociated using a heated (37°C) gentle-MACS Octo dissociator (Miltenyi Biotec) with an enzymatic dissociation system (Neonatal Heart Dissociation Kit; Miltenyi Biotec). The resulting cells were sedimented as described in the neonatal isolation and expanded for 2 passages before freezing. CFs were maintained in high-glucose DMEM supplemented with 1% penicillin-streptomycin and 10% FBS. CFs were used between passages 3 and 7 for experiments, with days to passage and passage number recorded.
Western Blotting/Immunoprecipitation and Analysis
Western blotting was performed as previously described. 30, 34 A list of primary and secondary antibodies, including manufacturer number and working concentration, may be found in Table I in the Data Supplement. Immunoprecipitation to detect activated RhoA was performed using a pulldown assay kit (Cytoskeleton, Inc.) according to manufacturer instructions.
Statistical Analysis
Statistics were performed with Prism 7 (GraphPad). Statistical analyses and experimental replicates are listed individually in the figure legends. Replicates in this study are biological (not technical) unless specifically noted otherwise. .05 for SAC/VAL compared with equimolar VAL. C, H&E staining of transverse sections through the papillary muscle further confirms SAC/VAL's significant effect against hypertrophic remodeling in response to pressure overload. Scale bar =1 mm. D and E, Systolic/diastolic LV internal diameter (ID) increase is prevented by SAC/VAL but not the molar equivalent of VAL. F and G, Systolic/diastolic volume increase is prevented by SAC/VAL but not the molar equivalent of VAL. Two-way ANOVA with repeated measures (time). H, Fractional shortening is significantly improved by SAC/VAL, but not the molar equivalent of VAL. Two-way ANOVA with repeated measures (time). I, Ejection fraction is significantly improved by SAC/VAL but not the molar equivalent of VAL. Two-way ANOVA with repeated measures (time). J, Myocyte cross-sectional area (CSA) is visualized by wheat germ agglutinin (WGA) staining. Nuclei are labeled with 4',6-diamidino-2-phenylindole (DAPI) (blue). Scale bar =100 μm. K, CSA is increased due to concentric hypertrophic remodeling induced by pressure overload (saline), and is decreased in SAC/VAL-treated mice significantly more so than equimolar VAL. One-way ANOVA, Tukey multiple comparisons test. n=5, 5, 6, and 7. *P<0.05 compared with saline;
RESULTS
SAC/VAL Is More Effective Than Molar Equivalent VAL at Preserving Cardiac Function in a Mouse Model of Pressure Overload-Induced HF
To gauge the efficacy of SAC/VAL at preserving systolic cardiac function in the context of direct comparison to VAL therapy alone, we used the TAC model of pressure overload-induced HF in adult male C57Bl6/J animals (experimental timeline in Figure IA SAC/VAL resulted in a significant decrease in cardiac hypertrophy at 28 days post-TAC relative to both saline and the molar equivalent of VAL (26 mg/kg), as determined by heart weight to tibia length ratio. Both SAC/ VAL and 52 mg/kg (2× molar equivalents) VAL conferred significant protection from hypertrophy ( Figure 1A ). This was confirmed by echocardiographic measurement of the LV mass, where the SAC/VAL regimen was associated with a significantly lower LV mass than equimolar VAL-which itself provided no significant antihypertrophic protection relative to the saline control ( Figure 1B  and 1C) . None of the regimens significantly affected kidney weight to tibia length ratio ( Figure IH in the Data Supplement), suggesting alterations to the blood pressure were not due to major changes in renal function. SAC/VAL is associated with significant decreases in systolic and diastolic internal dimension relative to the molar equivalent of VAL ( Figure 1D and 1E) beginning at 14 days and persisting throughout the experiment. SAC/VAL is also associated with significant decreases in systolic and diastolic volume relative to the molar equivalent of VAL ( Figure 1F and 1G) beginning at 21 days. Consequently, SAC/VAL is also associated with significant improvements relative to equimolar VAL in the systolic functional parameters fractional shortening ( Figure 1H ) and ejection fraction (Figure 2 ) at the 28-day time point. SAC/VAL and 52 mg/kg VAL regimen (2× molar equivalent) both provide significant functional improvement beginning at 14 days. Furthermore, SAC/ VAL is associated with significant decrease in cardiomyocyte cross-sectional area, as is the 2× VAL regimen (Figure 1J and 1K) . Cardiomyocyte isolated by Langendorff perfusion reveal that SAC/VAL treatment is associated with significant suppression of fetal gene re-expression (Acta1 and Myh7), retention of Myh6 expression, and reduced expression of natriuretic peptides ANF and BNP (Nppa and Nppb) relative to the molar equivalent of VAL ( Figure II in the Data Supplement).
SAC/VAL Is More Effective Than VAL at Ameliorating Cardiac Fibrosis, With Distinct Effects on CF Gene Expression
The effect of SAC/VAL on diastolic function was measured by E/A ratio and E/E′ ratio, which represent distinct indices of diastolic dysfunction (E/A in early dysfunction and E/E′ in more established disease). E/A was not statistically significantly changed by SAC/VAL relative to the molar equivalent of VAL at the terminal time point (Figure 2A) , whereas E/E′ values from both the intraventricular septum and the mitral valve revealed a trend (P=0.11 and 0.06, respectively) toward SAC/VAL-conferred protection from diastolic dysfunction relative to equimolar VAL alone ( Figure 2B ). Diastolic dysfunction is associated with increasing stiffness and fibrotic deposition, suggesting that SAC/VAL may modulate cardiac fibrosis more efficiently than the molar equivalent of VAL. In keeping with the E/E′ ratio, we found that hearts from mice treated with the SAC/VAL regimen were significantly less fibrotic than those treated with the molar equivalent of VAL ( Figure 2C ). Polarized light imaging of PicroSirius Red-stained sections revealed significant decreases in epicardial and interstitial fibrosis ( Figure 2D through 2F) . Both thin (green) and thick (red) fibers were affected, with no observable shift from thick to thin or vice versa. In contrast, there appeared to be no significant effect of SAC/VAL relative to the VAL equivalent in perivascular fibrosis. Interestingly, 52 mg/kg VAL (2× molar equivalent) was associated with significant protection from fibrosis (thin and thick fibers) in all 3 areas of interest. We hypothesized that the extent of fibrosis might best correlate with the number of fibroblasts in the heart (extent of fibroblast population expansion). Therefore, we stained for PDGFRα and vimentin, 2 markers of resident mesenchymal cells/CFs ( Figure 3A and 3B) . We found that while low-dose VAL led to a minor reduction in PDGFRα and vimentin + fibroblasts found in the heart post-TAC relative to saline, SAC/VAL was associated with a significant decrease in fibroblast population, displaying significantly less PDGFRα positivity than the molar equivalent of VAL ( Figure 3C and 3D) . Endothelial cells, which can also express vimentin, did not appear to be affected by drug regimens in terms of total capillary area ( Figure IIIA and IIIB in the Data Supplement), but average intercapillary distance within the transverse myocardium reflected the modulation in cardiomyocyte size shown in Figure 1J and 1K ( Figure IIIC in the Data Supplement). CF isolated from the hearts via Langendorff perfusion reveal that SAC/VAL treatment is associated with gene expression profiles consistent with decreased myofibroblast transition/activation (low Acta2 [smooth muscle alpha actin] and Postn), lower proliferation (low Ccna2, Ccne1, Sprr2b; high Cdkn1a), improved protection from oxidative damage (high Mt1), and decreased production of extracellular matrix molecules (low Col1a1, Col3a1, and Fn) compared with saline-treated controls ( Figure 3E ). High-dose VAL was also associated with these significant alterations in gene expression (and the addition of a sig- .05 for SAC/VAL compared with equimolar VAL. E, qRT-polymerase chain reaction (PCR) for gene expression in fibroblasts isolated by Langendorff perfusion of mouse hearts reveals that SAC/VAL effectively targets proliferation, activation, and extracellular matrix-associated gene expression. The equivalent dose of VAL has no statistically significant effect on any of these genes, while SAC/VAL confers significant changes that reflect a less pathological gene program. n=5, 5, 6, and 7. Two-way ANOVA, Tukey multiple comparisons test. *P<0.05 compared with saline; nificant increase in Tcf21, a potential marker of quiescent fibroblasts). 35 However, the molar equivalent VAL regimen failed to confer any statistically significant changes in gene expression in CF relative to saline controls-again indicating that SAC/VAL measurably improves on equimolar VAL as a cardiac therapeutic in the pressure overload model, with specific antifibrotic effects that are not solely attributable to the VAL portion of the molecule.
The Neprilysin Inhibitor Sacubitrilat Targets Myofibroblast Activation In Vitro
To further investigate the effects of SAC/VAL on CF as compared with VAL, we undertook studies in neonatal mouse CF (nCF) cultures. We found that pretreatment of nCF with increasing concentrations of ANF conferred a dose-dependent inhibition of Acta2 gene expression induced by 10 ng/mL TGF-β1 ( Figure 4A ). We confirmed this by recreating the experiment (this time including an unstimulated negative control) and assaying for the Postn and Tcf21 expression ( Figure 4B and 4C) . In each case, increasing doses of ANF pretreatment inhibited Postn and partially restored Tcf21 expression. A third iteration of this experiment revealed that the effect of ANF on activation/quiescence genes do not extend to cell cycle/ proliferation-associated genes, which are unresponsive to ANF in these experiments ( Figure 4D ). This was confirmed by adding Ang II to the stress stimulus (10 ng/ mL TGF-β1/1 μM Ang II), which resulted in significantly increased expression of the mitosis-associated genes Ccna2 and Cdk1, and significantly lower expression of the cell cycle inhibitor Cdkn1a-consistent with the abil- ity of Ang II to stimulate CF proliferation ( Figure 4E ). 30 Again, addition of ANF did not significantly alter cell cycle/proliferation gene expression but did significantly impair gene expression associated with myofibroblast transition and activation (Acta2, Col1a1, and Postn). Taken together, this set of experiments suggests that ANF signaling predominantly inhibits the gene program that signifies myofibroblast transition, whereas angiotensin signaling predominantly induces the gene program that signifies fibroblast proliferation. This is consistent with the dual function of SAC/VAL as a neprilysin inhibitor (inhibition of ANF degradation, potentiation of ANF signaling) and as an ARB (inhibition of Ang II-signaling).
To directly evaluate the effects of SAC versus VAL, we made use of the activated form of SAC (sacubitrilat). SAC has been shown to be converted to sacubitrilat by the liver in a CES1-dependent manner. 36 Interestingly, nCF express Ces1, and this expression is insensitive to stress stimuli-suggesting the possibility of direct conversion of SAC to sacubitrilat in CF ( Figure IV in the Data Supplement). To assess the effects of sacubitrilat on nCF exposed to stress stimuli, we repeated the experiment shown in Figure 4E , adding a condition in which 200 μM sacubitrilat was added to the ANF pretreatment ( Figure 5A ). Sacubitrilat was associated with significant decreases in Col1a1 and Postn relative to ANF pretreatment alone, as was expected. Unexpectedly, pretreatment with sacubitrilat was also associated with significant inhibition of cell cycle/proliferation-associated gene expression. To determine whether these effects were specific to sacubitrilat, we repeated the experiment, comparing how addition of VAL (200 μM) and VAL/sacubitrilat (200 μM each, SAC/VAL) to the pretreatment regimen compared with pretreatment with ANF alone. Figure 5B shows that while VAL pretreatment generally had few effects on nCF gene expression relative to ANF pretreatment alone (the exception was a significant decrease in Ccna2 expression), combining VAL and sacubitrilat in pretreatment resulted in significant decreases in Acta2, Col1a1, and Postn (myofibroblast transition/activation genes) coupled to inhibition of cell cycle genes (significantly lower Ccna2 and Cdk1, significantly higher Cdkn1a). To confirm that the significant changes in gene expression were mirrored at the protein level, we repeated the experiment and performed a Western blot for ACTA2, which was significantly decreased by the combination of sacubitrilat and VAL at 24 hours ( Figure 5C ).
Sacubitrilat-Mediated Protection From Myofibroblast Transition Is Mediated by PKG-Dependent Inhibition of RhoA Activation
We next asked whether sacubitrilat activity in nCF is via stabilizing ANF-NPR (natriuretic peptide receptor)-cGMP-PKG signaling. To do this, we made use of the VASP (vasodilator-stimulated phosphoprotein), which is phosphorylated at S239 with greater affinity by PKG than PKA, which preferentially phosphorylates S157. 37 Again, cells were pretreated with ANF, in the presence or absence of VAL or sacubitrilat, then stimulated with TGF-β1/Ang II to simulate stress. We found that sacubitrilat or the combination of VAL and sacubitrilat potentiates VASP-pS239, whereas VAL alone does not ( Figure 6A and 6B) . To confirm that sacubitrilat activity is predominantly transduced through cGMP/PKG, we made use of the indolocarbazole PKG inhibitor KT5822 (20 nmol/L). 38 In the absence of KT5822, we confirmed again that ANF-induced, PKGdependent induction of VASP-pS239 was potentiated by sacubitrilat and not VAL ( Figure 6C and 6D) . In the presence of KT5822, VASP-pS239 was completely lost in all conditions but the sacubitrilat treatment, which is itself significantly decreased from the degree of VASP-pS239 present in the sacubitrilat-treated nCF without KT5822 (see Discussion). This result confirms that PKG is required for sacubitrilat-induced signaling in nCF, which implies that ANF and the natriuretic peptide receptor pathway are indeed the operative signaling pathway that confers protection from myofibroblast transition.
To more closely explore the relationship between the potentiation of PKG signaling by sacubitrilat and its observed effects on inhibition of the signals that lead to myofibroblast transition, we focused on a protein called RhoA (Ras homolog gene family member A). RhoA is activated by TGF-β1 and initiates signaling pathways that induce stress fiber formation and the acquisition of mesenchymal properties. 39 Furthermore, inhibitors of RhoA effector molecules such as ROCK (Rho-associated protein kinase) have been evaluated in clinical trials targeting pulmonary arterial hypertension-also a disease involving significant organ remodeling. 40 RhoA is known to be phosphorylated by PKG at S188, which inhibits RhoA cytoskeletal reorganization functions while simultaneously protecting it from ubiquitination and subsequent proteasomal degradation. 41 We confirmed that sacubitrilat treatment potentiates RhoApS188 in nCF under the same conditions evaluated for VASP-pS239 ( Figure 6E and 6F) .
To determine the degree of RhoA functional inhibition in a clinically relevant manner, we evaluated CF isolated from 5 HF patients that had undergone left VAD (LVAD) implantation (termed heart failure cardiac fibroblasts, or HFCF). We characterized mRNA and protein from these HFCF (unstimulated or stimulated with TGF- . 20, 25 Notably, NPRA protein expression was recovered in any patientderived line save VAD2, which was a notable outlier in all other measures as well. We also found that PKG1A protein levels are insensitive to these experimental manipulations in all patient-derived lines, which when combined with the evidence from the PKG inhibition experiment points to PKG activity, not expression level, as the target of SAC/VAL. We performed a coimmunoprecipitation using beads conjugated to the Rho-binding domain of rhotekin, an effector of Rho signaling. Rhotekin only binds activated (GTP-bound) Rho, which allows for the direct comparison of total Rho to activated Rho. As expected, Rho activation was not inhibited by Y-27632, which inhibits a distinct downstream effector, p160/ROCK, although all HFCF showed measurable levels of total Rho protein in response to TGF-β1/Ang II/ ANF ( Figure 7A ). However, we found that the combination of sacubitrilat and VAL significantly reduced Rho activation for all HFCF ( Figure 7A ). Interestingly, while the combination of the 2 component drugs of SAC/VAL always successfully decreased Rho activation, there was variability as to which component was more effective in doing so alone; VADs 1, 3, and 4 were most responsive to sacubitrilat, and VAD2 was responsive only to VAL (Figures 7B through 7E) . Interestingly, there was also . We concluded from this set of experiments that in HFCF, the combination of sacubitrilat and VAL does indeed act to potentiate PKG-dependent inhibition of RhoA, a major effector of myofibroblast transition and activation. This was confirmed by the consistent decrease in ACTA2 expression in response to the combination of the 2 component drugs.
DISCUSSION
LCZ696 was identified as a significant improvement over standard of care (the ACE inhibitor enalapril) in patients with class II, III, or IV HF and reduced ejection fraction in the PARADIGM-HF trial. 13 In the ensuing years, a healthy discussion has arisen regarding the results and design of this trial-particularly the potential for understatement of adverse event rate due to both the entry criteria for the study and the run-in period design. 42 The wealth of clinical literature regarding LCZ696 has far outpaced the knowledge of how it mechanistically operates on the cellular level particularly in CF-although VAL's role as an AT 1 R blocker is well characterized in CF, what effects neprilysin inhibition has on CF (particularly in the context of pathological signaling) are effectively unknown.
This study was intended to dissect the role of SAC/ VAL in the setting of cardiac fibrosis. We found that SAC/ VAL, as expected, represented a significant advancement over equimolar low dose VAL alone in protection from cardiac functional decline in a mouse model of pressure overload-induced HF. SAC/VAL altered the pathological state of CF, yielding a gene expression program that was more reflective of quiescence than .05 relative to TGF-β1/Ang II/ANF. E, Sacubitrilat promotes the PKG-dependent phosphorylation of RhoA at S188, which inactivates RhoA (a major transducer of myofibroblast activation). F, Quantification of (E). One-way ANOVA with Tukey multiple comparisons test. *P<0.05 compared with vehicle. ND indicates not detected. myofibroblast activation-which VAL at an equivalent concentration was incapable of doing. We found that while VAL-treated animals had significantly fewer CF in the heart at the terminal time point than did control animals, SAC/VAL-treated animals had significantly fewer CF than low dose VAL-treated. In vitro, we were able to ascertain that both sacubitrilat and VAL ameliorated human patient-derived HFCF activation-and in nCF, sacubitrilat predominantly modulated activation gene expression, whereas VAL predominantly modulated proliferation gene expression.
Interestingly, in a recent study using a rat model of myocardial infarction, VAL, not sacubitrilat, was primarily responsible for the antifibrotic effects in CFs. 18 There is at first an apparent disconnect between this study and ours-as we found that VAL primarily altered proliferative capacity in the mouse CF while sacubtrilat affected myofibroblast transition and activation genes. This distinction was less clear in HFCF, where certain patient-derived lines responded better to sacubitrilat and others to VAL-with all lines being maximally responsive to the combination of the two. This previous study differs from ours in 3 important ways.
While our study made use of nCF, adult mouse pathological CF, and human HFCF, the other study used adult rat CF-potentially explaining some of the difference in results. Their study was also performed in myocardial infarction, whereas ours was performed in pressure overload-and we have shown that fibroblast transcriptional responses to these disease models are distinct. 30 Their study made use of radiolabeled proline uptake to determine fibrotic synthesis, as opposed to our study which focused mainly on transcription profiles in CF. The extent of temporal overlap between the development of a gene program that induces the myofibroblast transition and the development of an activated, extracellular matrix-secreting myofibroblast is still unresolved, and the results from these 2 studies suggest that this might be an excellent avenue for further investigation of the fibrotic response during pressure overload.
Interestingly, both of these studies reveal direct antifibrotic effects of natriuretic peptide-induced signaling on CFs-with their study focusing on BNP and ours on ANF. Perhaps most interesting of the results from our study was the set of findings detailing how ANF works directly on CF to promote a less activated gene expression profile. We consistently found that NPRA protein expression level was decreased in response to TGF-β1/Ang II stimulus in HFCF, consistent with literature and pointing to extended ligand lifetime as opposed to stabilization of receptor protein expression as the mechanism by which sacubitrilat promotes PKG signaling in fibroblasts. The dynamics of NPRA inactivation and downregulation are certainly an important subject for further study-not only in CF, but in all pathology-relevant cell types expressing NPRA. Simultaneously, we found that sacubitrilat/VAL consistently rescued HF patient-derived CF from pathological levels of Rho activation, whereasVAL alone had a less consistent effect. As RhoA can be inactivated by PKG-dependent phosphorylation at S188, and the increased ligand lifetime of ANF in the presence of sacubitrilat correlated with decreased Rho activation and ACTA2 expression, our data in these patient-derived cells suggest strongly that rescue of PKG signaling by sacubitrilat was the driving mechanism behind the decreased myofibroblast activation.
To this end, we indeed found PKG to be essential for sacubitrilat-mediated inhibition of myofibroblast transition, confirming the requirement for NPRA guanylate cyclase activity in maintaining a nonpathological state in CF. We observed that PKG1A (catalytic subunit) total protein levels were insensitive to stimulation with TGF-β1/ Ang II, suggesting that defects in NPRA/cGMP signaling in pathological CF do indeed stem from PKG1A activity and not PKG1A protein level. However, we also found that treating CF with sacubitrilat in the presence of the PKG inhibitor KT5822 did not fully ablate the PKG-dependent phosphorylation of VASP at S239. The incomplete inhibition of VASP-pS239 in KT5822 + /sacubitrilat cells likely has 2 root causes. While highly specific for PKG (IC 50 2 nmol/L for PKG versus 37 nmol/L for PKA), 43 literature suggests that use of KT5822 might potentiate PKA signaling and cross-phosphorylation of PKG targets. 38 Furthermore, 20 nmol/L KT5822 pretreatment was chosen to inhibit PKG (2 nmol/L IC 50 ) as much as possible, without strongly inhibiting PKA (37 nmol/L IC 50 )-but this dose was unlikely to fully inhibit PKG. It is possible that the addition of sacubitrilat potentiates PKG via ANF-NPRA-cGMP strongly enough that we were able to still see VASP-pS239 even in the presence of this dose of KT5822. Regardless, potential redundancy in PKG/PKA signaling is likely to be an important clinical consideration for the use of neprilysin inhibitors in the context of HF.
The data from this preclinical trial suggest that in addition to the known positive systemic effects of promoting PKG signaling (vasorelaxation, lowered blood pressure), less obvious direct effects on cells other than smooth or cardiac muscle exist as well. In this case, we have shown that the sacubitrilat component of SAC/ VAL is capable of directly modulating PKG signaling in CFs, which inhibits the expression of the myofibroblast transition-related gene program via promoting PKGdependent inhibition of Rho-mediated signaling.
